International Biotechnol... Share Discussion Threads

[speedsgh] 16/12/2020 11:30

Dividend Declaration - HTTPS://www.londonstockexchange.com/news-article/IBT/dividend-declaration/14794241 At the Annual General Meeting held on 15 December 2020, Shareholders approved the Company's dividend policy of making dividend payments, equivalent to 4 per cent. of the Company's Net Asset Value as at the last day of the preceding financial year (31 August), through two equal semi-annual distributions. The Directors have today declared the first Interim Dividend for the period ending 31 August 2021 in an amount of 14.2p per Ordinary Share. The first Interim Dividend will be payable on Friday, 29 January 2021 to holders of Ordinary Shares on the Register at the close of business on Tuesday, 29 December 2020 (ex-dividend Thursday, 24 December 2020).

[speedsgh] 10/11/2020 13:33

International Biotechnology Trust: Bypassing Binary Bets - HTTPS://www.itinvestor.co.uk/2020/11/international-biotechnology-trust/

[speedsgh] 19/10/2020 19:34

Int’l Biotech switches small-caps for ‘undervalued’ growth - HTTPS://citywire.co.uk/investment-trust-insider/news/int-l-biotech-switches-small-caps-for-undervalued-growth/a1413118

[panshanger1] 08/10/2020 19:21

All quiet here !!New ATH and plenty of momentum in this sector GLA

[shieldbug] 04/8/2020 12:02

Not so pleased to see how they calculate the dividend though. The 4% is calculated once a year and divided into two payments. So we don't get 2% of the mid July price.

[shieldbug] 04/8/2020 12:00

This year IBT bought back about £1m of shares (172,546 shares) at an average price of £5.82 and have just issued 75,000 shares at £7.94. Rarely see great benefit from buy backs but that looks impressive.

[caradog] 17/4/2020 09:45

The two US phase 3 trials of Remdesivir are still recruiting and won't be reporting before May. hTtps://clinicaltrials.gov/ct2/show/NCT04292730 hTtps://clinicaltrials.gov/ct2/show/NCT04292899 The similar Chinese trials had to be suspended because of lack of suitable patients. (Trump's incompetence will help to ensure plenty of US participants) Optimism in the press is based on the publication of a small uncontrolled trial in the NEJM, with promising but inconclusive results. Still, promising is good, for now. hTtps://www.ft.com/content/c59a385f-62e1-42a2-b8ac-2ecb44305e4e

[robizm] 17/4/2020 08:20

That is actually fake news and has been down played by the company itself. You need to be careful where you get your news from these days.

[shieldbug] 17/4/2020 07:46

More positive news from Gilead testing of Remdesivir on severe Covid patients in Chicago trials.

[shieldbug] 11/4/2020 06:40

The tide may well have turned here since Bernie pulled out of the US presidential race. In addition Bloomberg are reporting today some success in a trial of Gilead's remdesivir where two thirds of Covid 19 patients showed improvement. Gilead being IBT's second largest holding. Hopefully we will not be revisiting the lows of 3 weeks ago any time soon.

[panshanger1] 14/2/2020 17:07

Discount widening now

[speedsgh] 21/1/2020 13:59

The following blog is somewhat out-of-date (July 2019) but a useful read on the sector all the same... Boosting Returns With Biotech - HTTPS://www.itinvestor.co.uk/2019/07/boosting-returns-with-biotech/

[speedsgh] 21/1/2020 00:49

Yes, it would appear that the benefits of the attractive dividend policy have been more than nullified by NAV performance where IBT has noticeably lagged its peers over the past 5yrs. It would certainly be pleasing to see that change. The irony of course is that the discount to NAV has narrowed significantly over the same time period.

[mozy123] 20/1/2020 16:16

Quite disappointing, other healthcare/bio trusts on the move over the last few months. IBT nothing. Nothing for a fair few years, hopefully a rocket has been ignited somewhere in the portfolio.

[robsy2] 04/11/2019 18:36

Thanks all rambuten ,thanks for the factsheet. It looks interetsing but the intro is a bit over my head!! Welcome to our September Factsheet. Autumn is officially upon us and, quite literally, everything is turning brown. This month, we have ‘adroitly̵7; circumnavigated a seemingly endless horizon of icebergs, and one can at least enjoy the band’s jaunty music for a while longer. Reaching the calmer waters of macro-political stability has become quite the odyssey. Rest assured, we harbour no delusions of exceptional strength and are fully aware that much lies below the surface. We remain thusly focused on avoiding the obstacles ahead, be they white or brown. onto the others...

[rambutan2] 04/11/2019 16:22

As I’ve got bio exposure from likes of PRTC, ARIX and SYNC, i prefer BBH which has a broader remit, and a gd monthly factsheet with useful commentary. https://www.rns-pdf.londonstockexchange.com/rns/0495R_1-2019-10-24.pdf?_ga=2.256318990.467432130.1572854363-1758573039.1543496088

[the oak tree] 03/11/2019 19:26

Hi Robsy2 Am in here for the same reasons. Very much for the long term. Im afraid I don't have the answer though, not been good performance but will keep for the time being. Investments can lag, but feel being in a investment trust , they will change it up. Well thats one theory!

[robsy2] 02/11/2019 17:21

I have been a holder for a while but this has really trod water over the past few years ... not sure what to do . I just want to be invested in this area or similar healthcare as part of a long term thematic positioning in healthcare , medicine , biotech etc. I am wondering out loud if I am in the right place here . Anyone got any bright ideas? R

[speedsgh] 29/10/2019 13:13

Dividends, buybacks, share issuance and discount I am pleased to report that the Company's fifth and sixth dividend payments were made during the financial year. We paid out a dividend equal to 4% of NAV as at 31 August 2018 in two equal tranches on 31 January 2019 and 31 August 2019, equating to a 4.1% increase when compared with dividend payments in the previous year. In accordance with the Shareholder Circular dated 13 September 2016 and as a matter of best practice, the Board will be seeking Shareholder approval to continue the payment of dividends and a resolution will be put to Shareholders at the forthcoming Annual General Meeting (AGM)...

[shieldbug] 23/10/2019 10:29

IBT hit by pound strengthening and dividend payout?

[speedsgh] 07/10/2019 10:28

According to the most recent monthly factsheet, the NAV as at financial year end on 31/8/2019 was £239m (622p per share). HTTPS://ibtplc.com/wp-content/uploads/2019/09/August-Factsheet-2019.pdf Current dividend policy is to pay out an amount eqivalent to 4% of yr end NAV in two tranches. NAV as at 31/8/2018 was 699p which equated to a dividend of 28.0p in the current FY (2 x 14.0p payments) If NAV as at 31/8/2019 was 622p, this would appear to equate to a dividend of 24.75-25.0p over the next 12 months, which would represent a reduction of c.11-12%.

[sharesoc] 29/4/2019 09:54

You can meet the managers of International Biotechnology Trust at the Mello Trust and Funds Show. We all have discounted tickets available from ShareSoc, full members get an originally £49 ticket for the reduced price of £24.50 - hTTps://www.sharesoc.org/blog/education/learn-from-experts-at-the-mello-investment-trust-and-funds-conference/

[davebowler] 08/3/2019 10:31

QuoteData- Beating the odds view report Strategic positioning in mid-2018 helped International Biotechnology Trust (IBT) beat its benchmark over the past six months and close its discount to net asset value (NAV). This continued its outperformance of the US Nasdaq Biotechnology Index (NBI) over three and five years. Active management of the portfolio and an increased focus on larger mid-caps played out well in terms of IBT’s performance versus its peers. IBT’s manager is maintaining its established policy of active risk mitigation, designed to avoid exposure to binary events that can cause large swings in the share price (typically the results of the Phase III trials that provide the final confirmation of safety and efficacy before the FDA approves a treatment for marketing). This should be seen as another attraction to investors in the trust. IBT’s shares have recently moved to trade at a premium to NAV and it has been issuing stock, expanding the fund. SECTOR: SECTOR SPECIALIST - BIOTECHNOLOGY AND HEALTHCARE TICKER: IBT LN BASE CURRENCY: GBP (PENCE) PRICE: 634.00P NAV: 636.40P PREMIUM/(DISCOUNT): (0.4%) YIELD: 4.4% spacer spacer spacer ACCESS TO THE FAST-GROWING BIOTECH SECTOR charticon spacer spacer spacer spacer IBT is the longest-established of the London-listed funds specialising in the biotech/healthcare sector. It aims to achieve long-term capital growth by investing in biotechnology and other life sciences companies, and offers investors the highest yield in the sector while keeping its day-to-day running costs low. The portfolio is invested primarily in quoted companies, but IBT also has some exposure to unquoted compani